605 related articles for article (PubMed ID: 29894689)
1. Non-conventional Inhibitory CD4
Zappasodi R; Budhu S; Hellmann MD; Postow MA; Senbabaoglu Y; Manne S; Gasmi B; Liu C; Zhong H; Li Y; Huang AC; Hirschhorn-Cymerman D; Panageas KS; Wherry EJ; Merghoub T; Wolchok JD
Cancer Cell; 2018 Jun; 33(6):1017-1032.e7. PubMed ID: 29894689
[TBL] [Abstract][Full Text] [Related]
2. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
3. Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.
Zhang B; Chikuma S; Hori S; Fagarasan S; Honjo T
Proc Natl Acad Sci U S A; 2016 Jul; 113(30):8490-5. PubMed ID: 27410049
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
5. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
6. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
7. Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1.
Chen WJ; Hu XF; Yan M; Zhang WY; Mao XB; Shu YW
Atherosclerosis; 2016 Jan; 244():108-12. PubMed ID: 26615520
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
9. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
10. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
Front Immunol; 2020; 11():576743. PubMed ID: 33519801
[TBL] [Abstract][Full Text] [Related]
11. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
12. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
13. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
Taylor NA; Vick SC; Iglesia MD; Brickey WJ; Midkiff BR; McKinnon KP; Reisdorf S; Anders CK; Carey LA; Parker JS; Perou CM; Vincent BG; Serody JS
J Clin Invest; 2017 Sep; 127(9):3472-3483. PubMed ID: 28825599
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade augments humoral immunity through ICOS-mediated CD4
Zhang M; Xia L; Yang Y; Liu S; Ji P; Wang S; Chen Y; Liu Z; Zhang Y; Lu S; Wang Y
Int Immunopharmacol; 2019 Jan; 66():127-138. PubMed ID: 30448635
[TBL] [Abstract][Full Text] [Related]
15. PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy.
Zeng W; Qin S; Wang R; Zhang Y; Ma X; Tian F; Liu XR; Qin X; Liao S; Sun L; Lin Y
Cell Death Dis; 2020 Feb; 11(2):119. PubMed ID: 32051396
[TBL] [Abstract][Full Text] [Related]
16. Altered frequency of CD8
Rostamzadeh D; Haghshenas MR; Daryanoosh F; Samadi M; Hosseini A; Ghaderi A; Mojtahedi Z; Babaloo Z
J Cell Physiol; 2019 Jul; 234(7):11986-11998. PubMed ID: 30623416
[TBL] [Abstract][Full Text] [Related]
17. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.
Goding SR; Wilson KA; Xie Y; Harris KM; Baxi A; Akpinarli A; Fulton A; Tamada K; Strome SE; Antony PA
J Immunol; 2013 May; 190(9):4899-909. PubMed ID: 23536636
[TBL] [Abstract][Full Text] [Related]
18. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.
Teigler JE; Zelinskyy G; Eller MA; Bolton DL; Marovich M; Gordon AD; Alrubayyi A; Alter G; Robb ML; Martin JN; Deeks SG; Michael NL; Dittmer U; Streeck H
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904197
[TBL] [Abstract][Full Text] [Related]
19. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
Toor SM; Syed Khaja AS; Alkurd I; Elkord E
Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]